Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable ...

A vial containing Moderna's COVID vaccine. A deal related to the vaccine's patents clears the way for the pharma company's vaccine pipeline. Shares of Moderna on Wednesday surged to their highest in ...

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

Pfizer and Moderna are diligently working to launch new products and turn things around. And if their strategies pan out, ...